Anavex Life Sciences Corp.

AVXL · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analyst

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.7%

Institutions40.8%

Public / Other

Income Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$51.41M	-$52.88M	-$55.76M	-$50.99M	–	–	–	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$46.38M	-$43.00M	-$47.51M	–	–	-$26.28M	-$26.29M	-$17.45M	-$13.46M	-$14.74M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	–	–	$-0.54	$0.00	$0.00	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$0.00	–	–	–	–	–	–	–	$0.00

Balance Sheet

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Cash and highly liquid short-term investments the company can access almost immediately.	$102.58M	$132.19M	$151.02M	$149.16M	$152.11M	$29.25M	$22.19M	–	–	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$103.81M	$135.57M	$154.39M	$152.70M	$161.62M	$34.54M	$25.33M	$24.38M	$27.84M	$9.50M
Everything the company owes — debt, unpaid bills, and other obligations.	$8.95M	$15.30M	$12.53M	$10.21M	$10.80M	$7.31M	–	–	$3.58M	$3.19M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$94.87M	$120.26M	$141.85M	$142.49M	$150.82M	$27.24M	$20.29M	$20.49M	$24.25M	$6.31M

Cash Flow Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$39.04M	-$30.81M	-$27.79M	-$24.24M	-$30.38M	-$21.29M	-$18.53M	-$12.58M	-$9.02M	-$9.24M

	You	Peer avg
Revenue Growth	–	+67.0%
ROE	-12.8%	-184.9%

Anavex Life Sciences Corp.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison